The story unfolds all too frequently. Parents, worried about their baby’s fever and severe abdominal pain, visit the emergency room — then learn their precious child has neuroblastoma, a debilitating pediatric cancer. As little as two years ago, all children with neuroblastoma received the exact same treatment: Chemotherapy, bone marrow transplant, surgery and radiation. But today, treatments can be tailored to the individual, delivering effective, targeted and less toxic treatments. This approach, one component of “personalized medicine,” requires quick identification of the specific cancer type and access to genetic information about the tumor.
Virtual Microscopy to Microarray, or VM2M, will make this access a reality. An effort by the Research Institute at Nationwide Children’s Hospital, Childrens Hospital Los Angeles and the Ohio Supercomputer Center, VM2M will give physicians and cancer researchers a comprehensive repository of tumor tissue samples and their corresponding genetic markers.
VM2M will provide two currently unavailable requirements for creating personalized treatment plans: 24/7 access to both the pathology of specific cancer tumors and the genetic information of the tumors.
To empower quick and accurate access, the Center for Childhood Cancer at The Research Institute at
Nationwide Children’s Hospital developed custom computer software that allows multiple pathologists to simultaneously and securely review, via the Internet, digital, diagnostic-quality microscopy scans of diseased tissue with the corresponding molecular expression data. Virtual microscopy scans are paired with each sample’s genetic code, or microarray, created by Childrens Hospital Los Angeles, while OSC provided a secure repository and hosted the development platform during the project’s first phase.
“OSC’s powerful, memory-intensive data management and networking resources enabled storing organizing and retrieving this information,” said David Billiter, director, research informatics core, Nationwide’s Center for Childhood Cancer. “We are now poised to explore the next phase of development for VM2M by producing value-added functionality and moving into a production-supported environment.“
That means the VM2M project, when fully implemented, will help children and adults fight all cancer with the best treatment option possible — one custommade for the individual.
Project leads: The Research Institute at Nationwide Children’s Hospital, Childrens Hospital Los Angeles, Children’s Oncology Group & OSC
Research title: Integrated virtual microscopy & molecular analysis software for enhanced cancer diagnosis
Funding source: U.S. Department of Health & Human Services, through the Ohio Board of Regents